<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(3)</volume><submitter>Micheli L</submitter><funding>Università degli Studi di Firenze</funding><pubmed_abstract>Chemotherapy-induced neuropathy (CIN) is a major dose-limiting side effect of anticancer therapy that can compel therapy discontinuation. Inadequate analgesic efficacy of current pharmacological approaches requires the identification of innovative therapeutics and, hence, the purpose of this study is to conduct a preclinical evaluation of the efficacy of DDD-028, a versatile pentacyclic pyridoindole derivative, against paclitaxel-induced neuropathic pain. In two separate experiments, DDD-028 was administered per os acutely (1-25 mg kg&lt;sup>-1&lt;/sup>) or repeatedly (10 mg kg&lt;sup>-1&lt;/sup>) in paclitaxel-treated rats. The response to mechanical noxious stimulus (paw pressure) as well as to non-noxious mechanical (von Frey) and thermal (cold plate) stimuli was investigated. Acute administration </pubmed_abstract><journal>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</journal><pagination>2008-2020</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8608957</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pain Relieving and Neuroprotective Effects of Non-opioid Compound, DDD-028, in the Rat Model of Paclitaxel-Induced Neuropathy.</pubmed_title><pmcid>PMC8608957</pmcid><pubmed_authors>Ghelardini C</pubmed_authors><pubmed_authors>Rajagopalan P</pubmed_authors><pubmed_authors>Rajagopalan R</pubmed_authors><pubmed_authors>Carrino D</pubmed_authors><pubmed_authors>Lucarini E</pubmed_authors><pubmed_authors>Pacini A</pubmed_authors><pubmed_authors>Toti A</pubmed_authors><pubmed_authors>Di Cesare Mannelli L</pubmed_authors><pubmed_authors>Parisio C</pubmed_authors><pubmed_authors>Micheli L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pain Relieving and Neuroprotective Effects of Non-opioid Compound, DDD-028, in the Rat Model of Paclitaxel-Induced Neuropathy.</name><description>Chemotherapy-induced neuropathy (CIN) is a major dose-limiting side effect of anticancer therapy that can compel therapy discontinuation. Inadequate analgesic efficacy of current pharmacological approaches requires the identification of innovative therapeutics and, hence, the purpose of this study is to conduct a preclinical evaluation of the efficacy of DDD-028, a versatile pentacyclic pyridoindole derivative, against paclitaxel-induced neuropathic pain. In two separate experiments, DDD-028 was administered per os acutely (1-25 mg kg&lt;sup>-1&lt;/sup>) or repeatedly (10 mg kg&lt;sup>-1&lt;/sup>) in paclitaxel-treated rats. The response to mechanical noxious stimulus (paw pressure) as well as to non-noxious mechanical (von Frey) and thermal (cold plate) stimuli was investigated. Acute administration </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2025-04-04T14:53:59.181Z</modification><creation>2022-02-11T13:26:21.333Z</creation></dates><accession>S-EPMC8608957</accession><cross_references><pubmed>34312766</pubmed><doi>10.1007/s13311-021-01069-8</doi></cross_references></HashMap>